Upload
s
View
214
Download
1
Embed Size (px)
Citation preview
All cause mortalityMancini 2006 – high CV risk RR 0,50 [0,40 – 0,62]Mancini 2006 – low CV risk RR 0,53 [0,44 – 0,64]Soyseth 2007 HR 0,57 [0,38 – 0,87]Keddissi 2007* OR 0,99 [0,51 – 1,94]Van Gestel 2008** HR 0,67 [0,52 – 0,86]
COPD mortalityFrost 2007 – cohort study OR 0,29 [0,16 – 0,52]Frost 2007 – case-control study OR 0,19 [0,08 – 0,47]
COPD hospitalizationsMancini 2006 – high CV risk RR 0,72 [0,56 – 0,92]Mancini 2006 – low CV risk RR 0,74 [0,67 – 0,82]
COPD exacerbationsBlamoun 2008 OR 0,43 [0,18 – 0,99]
Intubations for COPDBlamoun 2008 OR 0,10 [0,03 – 0,36]
Decline in lung functionKeddissi 2007 – FEV1 OR 0,27 [0,12 – 0,58]Keddissi 2007 – FVC OR 0,52 [0,34 – 0,80]
Myocardial infarctionMancini 2006 – high CV risk RR 0,48 [0,39 – 0,58]Mancini 2006 – low CV risk RR 0,69 [0,48 – 1,00]
0,2 0,4 0,6 0,8 1 1,2 1,4Favours active treatment Favours control
Placebo Statin
No. of Exacerbations per Person-Yr
250
No
. of
Par
tici
pan
ts
200
150
100
50
0
0 0,10-1,50 0,51-3,00 3,01-4,50 4,51-6,00 6,01-7,50 ≥ 7,51
Total No.of Patients
Placebo
Placebo
P = 0,34 by long-rank test
Statin
447
1,0
0,9
0,8
0,7
0,6
0,5
0,4
0,3
0,2
0,1
0,00 100 200 300 400 500 600 700 800 900 1000 1100 1200
292 (65,3)Statin
Follow-up (days)
Pro
po
rtio
n o
f P
atie
nts
wit
ho
ut
Exa
cerb
atio
n
430 293 (68,1)
Patients with TreatmentFailure (no./%)